相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
-20℃
- 保质期:
12个月
- 英文名:
Recombinant Chemokine C-X3-C-Motif Receptor 1 (CX3CR1)
- 库存:
1000
- 供应商:
上海信裕
| Organism species | Mus musculus (Mouse) |
| Product No. | xy523Mu01 |
| Source | Prokaryotic expression |
| Host | E.coli |
| Purity | > 95% |
| UOM | 50ug |
| Predicted Molecular Mass | n/a |
| Concentration | n/a |
| Applications | SDS-PAGE; WB; ELISA; IP. |
| Endotoxin Level | <1.0EU per 1µg (determined by the LAL method) |
| Formulation | Supplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl. |
Stability Test: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37oC for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.
Protein bands: 10kDa, 14kDa, 18kDa, 22kDa, 26kDa, 33kDa, 44kDa and 70kDa.
Double intensity bands: The 26kDa, 18kDa, 10kDa bands are at double intensity to make location and size approximation of proteins of interest quick and easy.
趋化因子C-X3-C-基元受体1(CX3CR1)重组蛋白Ready-to-use: No need to heat, dilute or add reducing agents before use.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验趋化因子介导的生物治疗 趋化因子是一类分子质量为8~11kDa的细胞因子样的分泌蛋白,可分为四类:即C-C,C-X-C,C-X3-C和XC趋化因子。其受体属于七次跨膜结构域G蛋白偶联受体。 将不同类型的趋化因子导人肿瘤细胞,能强化宿主抗肿瘤免疫反应。应用方法包括:将趋化因子基因导人肿瘤细胞,将重组蛋白注射人肿瘤,将趋化因子与肿瘤抗原结合的融合蛋白注入肿瘤,或者将趋化因子基因转导入DC或基质细胞。 使用单一趋化因子的疗法 将CCLl、CCL
Size Price (RMB) AL0103050 (6 x 50ųl) 6,042.68 AL0103200 (6 x 200ųl) 19, 752.40 AL0103500 (6 x 500ųl) 45,092.65 CFPE700-新一代无细胞蛋白表达试剂盒(小麦胚芽) 新一代无细胞蛋白质表达试剂盒(小麦胚芽)是一种低成本、高灵活性、高产量重组蛋白表达系统,采用便捷的protocol可在一天
强大而可靠的技术 Gateway技术是克隆和亚克隆DNA序列的一项新颖的通用系统,便于功能基因的分析和蛋白质的表达。一旦进入这个多功能的操作系统,DNA片段可以通过位点特异的重组在载体之间转移。 Gateway技术是基于已研究的非常清楚的λ噬菌体位点特异重组系统(attB x attP →attL x attR)。BP和LR两个反应就构成了Gateway技术(表1和图2)。BP反应是利用一个attB DNA片段或表达克隆和一个attP供体载体之间的重组反应,创建一个入门克隆。LR反应是一个
技术资料暂无技术资料 索取技术资料




